Figure 4From: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Sequence analysis of CDH1 exon 9 missense mutations. In the tumours of two patients, CDH1 exon 9 missense mutations were detectable and caused amino acid changes D402H or A408V.Back to article page
